← All trials
NCT04691765
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2021
- Primary completion
- Apr 30, 2021
- Completion date
- Apr 30, 2022
- First posted
- Dec 31, 2020
- Last posted
- Dec 31, 2020
- Enrollment
- 12
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sunnybrook Health Sciences CentreLead sponsor
- Swedish Orphan BiovitrumCollaborator
- Swedish Orphan BiovitrumCollaborator
- University of TorontoSponsor investigator
- University of TorontoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.